COMMENT| VOLUME 378, ISSUE 9809, P2056-2057, DECEMBER 17, 2011

High-risk prostate cancer: treat the prostate

Matthew R Cooperberg

Published:November 03, 2011DOI:https://doi.org/10.1016/S0140-6736(11)61254-3

Hundreds of thousands of men are diagnosed with clinically localised prostate cancer every year, and each faces a complex treatment decision with little high-quality evidence to help choose among treatments. Successfully completed, randomised trials of active treatments for localised prostate cancer are, unfortunately, scarce; a large systematic review commissioned by the US Agency for Healthcare Research and Quality noted that insufficient evidence exists to make conclusions about the relative benefits and harms of treatments.

The US Institute of Medicine has identified prostate cancer as among the USA’s top 25 priorities for future comparative effectiveness research.

This article is available free of charge.

Simply log in to access the full article, or register for free if you do not yet have a username and password.

Already registered?

Forgot password?

Not yet registered?

References

1.
- Wilt TJ
- MacDonald R
- Rutks I
- et al.
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Ann Intern Med. 2008; 148: 435-448
View in Article
2.
- Institute of Medicine
Initial national priorities for comparative effectiveness research.National Academies Press, Washington, DC2009: 1-253
View in Article
- Google Scholar
3.
- Warde P
- Mason M
- Ding K
- et al.
- for the NCIC CTG PR.3/MRC UK PR07 investigators
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Lancet. 2011; (published online Nov 3.)https://doi.org/10.1016/S0140-6736(11)61095-7
View in Article
4.
- Singh J
- Trabulsi EJ
- Gomella LG
The quality-of-life impact of prostate cancer treatments.

Curr Urol Rep. 2010; 11: 139-146
View in Article
5.
- Wei JT
- Dunn RL
- Litwin MS
- Sandler HM
- Sanda MG
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.

Urology. 2000; 56: 899-905
View in Article
6.
- Widmark A
- Klepp O
- Solberg A
- et al.
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Lancet. 2008; 373: 301-308
View in Article
7.
- Thompson I
- Thrasher JB
- Aus G
- et al.
Guideline for the management of clinically localized prostate cancer: 2007 update.

J Urol. 2007; 177: 2106-2131
View in Article
8.
- Mohler J
- Bahnson RR
- Boston B
- et al.
NCCN clinical practice guidelines in oncology: prostate cancer.

J Natl Compr Canc Netw. 2010; 8: 162-200
View in Article
- PubMed
- Google Scholar
9.
- Lu-Yao GL
- Albertsen PC
- Moore DF
- et al.
Survival following primary androgen deprivation therapy among men with localized prostate cancer.

JAMA. 2008; 300: 173-181
View in Article
10.
- Bechis SK
- Carroll PR
- Cooperberg MR
Impact of age at diagnosis on prostate cancer treatment and survival.

J Clin Oncol. 2011; 29: 235-241
View in Article
11.
- Lu-Yao GL
- Albertsen PC
- Moore DF
- et al.
Outcomes of localized prostate cancer following conservative management.

JAMA. 2009; 302: 1202-1209
View in Article
12.
- Zelefsky MJ
- Eastham JA
- Cronin AM
- et al.
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

J Clin Oncol. 2010; 28: 1508-1513
View in Article
13.
- Cooperberg MR
- Vickers AJ
- Broering JM
- Carroll PR
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Cancer. 2010; 116: 5226-5234
View in Article